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Combining poxvirus-based immunotherapies which “step
on the gas” to activate tumor antigen-specific T cell
immune responses with immune checkpoint inhibitors
(ICIs) which “release the brakes” on the immune system
is a promising direction for enhancing cancer immu-
notherapy. Evidence for the potential clinical benefit from
combination immunotherapy was obtained in a Phase I
dose escalation trial. Cohorts of prostate cancer (mCRPC)
patients were treated with a fixed dose of PROSTVAC, a
poxvirus-based active immunotherapy, plus escalating
doses of Ipilimumab, an anti-CTLA-4 ICI. The median
overall survival (mOS) of 31.6 months [1,] from the
combined cohorts was notably longer than the mOS of
mCRPC patients from an independent randomized Phase
II study (PROSTVAC alone 25.1 months versus placebo
16.6 months; the most pronounced survival benefit
(8.5 months) in mCRPC to date) [2]. This potentially
synergistic combination of PROSTVAC and Ipilimumab
warrants further exploration.
We modeled the benefit of combining poxvirus-based
immunotherapy with CTLA-4 blockade using MVA-BN-
HER2, which is being developed for breast cancer. In pre-
clinical studies a dramatic increase in mOS was observed
in a therapeutic CT26-HER2 lung metastasis model when
mice were treated with MVA-BN-HER2 plus CTLA-4
blockade compared to either treatment alone. The
improved survival with the combination therapy was
accompanied by a striking increase in the magnitude and
functional quality of tumor infiltrating HER-2 specific
CD8 T cells [3].
Additional ICIs are identified in our preclinical studies
as promising candidates for combining with poxvirus-
based immunotherapies. Immune checkpoint protein
expression is normally induced on activated T cells to
regulate activity, and we found that MVA-BN-HER2 treat-
ment resulted in activated CD8 T cells and elevated
expression of PD-1, TIM-3, or ICOS. However, immune
checkpoint proteins are chronically elevated on exhausted
T cells in an immunosuppressive tumor microenviron-
ment. In untreated tumor-bearing mice, a potentially
exhausted T cell phenotype was found on CD4 and
CD8 T cells characterized by increased expression or co-
expression of PD-1, TIM-3, and LAG-3. We compared
treatment of MVA-BN-HER2 alone or in combination
with ICI antibodies against these immune checkpoint
molecules in solid or metastatic CT26-HER2 tumor
models. Improved survival was observed with several dif-
ferent combinations, and synergistic efficacy was indicated
using the Chou-Talalay method [4]. These studies provide
data and rationale for combining poxvirus-based immu-
notherapies with a variety of ICIs in the clinic.
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